Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms
Authors:
Open Access
- 11 March 2020
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (10) , 1228-1235
Abstract
Randomized clinical trials (RCTs) are the gold standard in producing clinical evidence of efficacy and safety of medical interventions. More recently, a new paradigm is emerging—specifically within the context of preauthorization regulatory decision‐making—for some novel uses of real‐world evidence (RWE) from a variety of real‐world data (RWD) sources to answer certain clinical questions. Traditionally reserved for rare diseases and other special circumstances, external controls (eg, historical controls) are recognized as a possible type of control arm for single‐arm trials. However, creating and analyzing an external control arm using RWD can be challenging since design and analytics may not fully control for all systematic differences (biases). Nonetheless, certain biases can be attenuated using appropriate design and analytical approaches. The main objective of this paper is to improve the scientific rigor in the generation of external control arms using RWD. Here we (a) discuss the rationale and regulatory circumstances appropriate for external control arms, (b) define different types of external control arms, and (c) describe study design elements and approaches to mitigate certain biases in external control arms. This manuscript received endorsement from the International Society for Pharmacoepidemiology (ISPE).Keywords
This publication has 31 references indexed in Scilit:
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.American Journal of Epidemiology, 2016
- Guidelines for good pharmacoepidemiology practice (GPP)Pharmacoepidemiology and Drug Safety, 2015
- Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies2013
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Constructing Inverse Probability Weights for Marginal Structural ModelsAmerican Journal of Epidemiology, 2008
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial ResultsMedical Care, 2007
- Immortal time bias in observational studies of drug effectsPharmacoepidemiology and Drug Safety, 2007
- Channeling bias in the interpretation of drug effectsStatistics in Medicine, 1991
- Equipoise and the Ethics of Clinical ResearchNew England Journal of Medicine, 1987